Broad Commercialization and Scale-Up of Revio Enables Researchers with 15 Times More HiFi Data and High-Quality Human Genomes for Under $1,000 MENLO PARK, Calif., March 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB),…
MENLO PARK, Calif., Feb. 27, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in Cowen’s 43rd…
MENLO PARK, Calif., Feb. 16, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2022. Fourth quarter results Received record…
End-to-End Solutions Planned to Support Key Customer Applications With Increased Cost Flexibility on Long-Read Sequencing Systems MENLO PARK, Calif., Feb. 7, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer…
MENLO PARK, Calif., Feb. 2, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2022…
MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ — Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it has priced its previously announced underwritten public offering of 17,500,000…
MENLO PARK, Calif., Jan. 24, 2023 /PRNewswire/ — Pacific Biosciences of California, Inc. (Nasdaq: PACB) ("PacBio") today announced that it intends to offer and sell $150.0 million of shares of…
MENLO PARK, Calif., Jan. 13, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today celebrated long-read sequencing being named Nature Methods’ “Method of the Year 2022.” Nature Methods had recognized…
PacBio also Releases Preliminary Fourth Quarter 2022 Revenue, Shares Positive Onso Beta Feedback, and Launches the PacBio Compatible Program MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB),…
MENLO PARK, Calif., Jan. 9, 2023 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of highly accurate sequencing solutions, today announced a collaboration with the University of Tokyo, Graduate School of…
MENLO PARK, Calif., Dec. 28, 2022 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following events…
Researchers to Investigate Genetic Variants Associated with Rare Pediatric Diseases MENLO PARK, Calif., Dec. 6, 2022 /PRNewswire/ — PacBio, a leading developer of high-quality, highly accurate sequencing solutions, today announced…
MENLO PARK, Calif., Nov. 11, 2022 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that it will be participating in the following…
MENLO PARK, Calif., Nov. 7, 2022 /PRNewswire/ — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2022. Third quarter results Revenue of $32.3 million, a…
World Class Team Will Provide Strategic Guidance and Direction for PacBio’s Research and Development Activities MENLO PARK, Calif., Nov. 2, 2022 /PRNewswire/ — PacBio (NASDAQ: PACB), a leading developer of…
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.